Article

Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial

2019-10-14

Abstract excerpt

<title>Abstract</title> <p>BACKGROUND Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder of childhood with a devastating disease course. Several targeted gene therapies and molecular approaches have been or are currently tested in clinical trials; however, a causative therapy is still not available and best supportive care is limited to oral glucocorticoids with numerous long-term side effec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a92dc098-c25b-5190-a7b4-a91a93acec5e
DOI: 10.21203/rs.2.10085/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trialDOI 10.21203/rs.2.10085/v2Read

Drug development progress in duchenne muscular dystrophySemantic proximity Read

Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update.Semantic proximity Read

From Bench to Bedside: A Meta-Analysis of Translational Research in Duchenne Muscular DystrophySemantic proximity Read

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular DystrophySemantic proximity Read

New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics.Semantic proximity Read

Pharmacological prospects in the treatment of Duchenne muscular dystrophy.Semantic proximity Read

Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical TrialsSemantic proximity Read

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Semantic proximity Read

Duchenne muscular dystrophy: Drug development and regulatory considerations.Semantic proximity Read

Emerging drugs for Duchenne muscular dystrophySemantic proximity Read

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialSemantic proximity Read

Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophySemantic proximity Read